6:01 PM
 | 
Dec 14, 2011
 |  BC Extra  |  Company News

Tarsa revises NDA timeline for oral salmon calcitonin

Tarsa Therapeutics Inc. (Philadelphia, Pa.) pushed back its regulatory timeline for Ostora oral recombinant salmon calcitonin and now plans to submit an NDA to FDA in 2H12 for the postmenopausal osteoporosis product. Tarsa had planned to submit the application...

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >